Skip to content
Head to head

Kodiak Sciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: KOD · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

KOD +390.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
KODVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price97.17515.02
Change today-0.75%-1.08%
1-year return+396.0%+22.0%
Market cap$6.35B$130.58B
52-week range20.38 – 112.79412.27 – 568.67
Valuation
P/E (TTM)-23.8233.14
P/E percentile, own 5-yr range0th99th
P/B506.096.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-4.3215.32
Net profit (TTM)$-282.51M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-172.81M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership105.5%96.8%
Insider activity (12mo)33 buy / 7 sell28 buy / 22 sell
Short interest (% of float)12.9%1.9%
Analyst consensus86% buy / 14% hold (7)95% buy / 5% hold (21)
Analyst price target$127 (+31%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees1246,400
Founded20091989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.